The discolouration is a normal, harmless effect of the drug and usually disappears within 24 hours after the last dose. If the colour persists for longer than a few days, contact a healthcare professional to rule out other causes.
Yes, phenazopyridine may be taken alongside antibiotics to relieve discomfort while the antibiotic treats the infection. However, it does not replace the need for antimicrobial therapy.
The MHRA has not granted a marketing authorisation for phenazopyridine, primarily due to concerns about safety with prolonged use and the availability of alternative treatments.
Patients with moderate to severe hepatic impairment should use phenazopyridine only under medical supervision, and treatment should be limited to the shortest possible duration to minimise the risk of liver-related adverse events.
The colour change can interfere with urine-based dipstick tests (e.g., for blood), but it does not cause false-positive results for illicit drugs. If a drug test is required, inform the testing centre that you have recently taken phenazopyridine.
Look for cyanosis (bluish skin, especially lips and fingertips), shortness of breath, headache, fatigue, or a chocolate-brown colour of blood. These symptoms require immediate medical attention.
Phenazopyridine is not approved for use in individuals under 18 years of age because safety and efficacy have not been established in this group.
Phenazopyridine is classified as Pregnancy Category C. It should be used only if the expected benefit outweighs the potential risk to the fetus, and only after consulting a healthcare provider.
The recommended maximum duration is six days without medical review. Extending therapy beyond this period increases the risk of serious adverse effects such as methemoglobinemia.
No specific foods need to be avoided, but limiting alcohol consumption is advisable to reduce additional strain on the liver.
Phenazopyridine is a urinary analgesic classified in the Bladder & Urinary therapeutic group. It is supplied as a 200 mg oral pill. In the United Kingdom the Medicines and Healthcare products Regulatory Agency (MHRA) has not granted a marketing authorisation for phenazopyridine, so it is not available as a licensed product on the UK market. It may be prescribed or dispensed in other jurisdictions for short-term relief of urinary tract discomfort.
Phenazopyridine exerts a local anaesthetic effect on the mucosa of the urinary tract. After oral ingestion the drug is rapidly absorbed, reaches the kidneys, and is excreted unchanged in the urine. While present in the urinary tract it:
Onset of symptom relief typically occurs within 30 minutes, with the effect lasting for several hours. Because its action is confined to the urinary lining, systemic effects are limited in healthy individuals.
Phenazopyridine is not licensed in the UK. In countries where it is approved (e.g., United States Food and Drug Administration), the indicated uses are:
It is intended solely for symptomatic relief and does not treat the underlying infection. Antibiotic therapy must be used concurrently when a urinary infection is present.
Absolute contraindications
Known hypersensitivity to phenazopyridine or any of its excipients.
Severe renal impairment (eGFR < 30 mL/min/1.73 m²).
Relative contraindications
Moderate hepatic dysfunction - dose may need adjustment, and treatment duration should be limited.
G6PD deficiency - increased risk of haemolysis.
Pregnancy (Category C) and breastfeeding - use only if the potential benefit outweighs the risk.
Children under 18 years of age - safety and efficacy have not been established.
Patients with a history of methemoglobinemia or severe anaemia should avoid phenazopyridine.
If any of these serious signs occur, medical attention should be sought immediately.
| Interaction Type | Example | Clinical relevance | |||| | CYP-enzyme inhibition | Strong CYP2C9 or CYP3A4 inhibitors (e.g., fluconazole) | May increase phenazopyridine plasma concentrations, raising the risk of haemolysis or methemoglobinemia. | | Additive CNS depression | Other analgesics (e.g., opioids) | May enhance sedation; monitor for excessive drowsiness. | | Laboratory assay interference | Urine dipsticks, urine culture | Orange-red urine can give false-positive results for blood or alter colour-based tests. |
Patients should disclose all prescription medicines, over-the-counter products, herbal supplements and vitamins before starting phenazopyridine.
Dose adjustments for renal or hepatic impairment are not formally defined; clinicians usually limit duration and monitor for adverse effects.
This article provides educational information about phenazopyridine and is not a substitute for professional medical advice. Treatment decisions, including the use of unlicensed or off-label medications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes only and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
